Lytix Biopharma ASA LYTIX

OSL · Norway · Health Technology

NOK 8.26-0.50 (-5.71%)

Market closed· Oct 1, 2026, 2:25 PM UTC· NOK · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

Lytix Biopharma ASA LYTIX

OSL · Norway · Health Technology

NOK 8.26-0.50 (-5.71%)

Market closed· Oct 1, 2026, 2:25 PM UTC· NOK · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

-20.58% · 6MFull-screen chart

Open NOK 8.78High NOK 8.78Low NOK 8.04Close NOK 8.26Volume 12.04K

Oct 1, 2026

Charts by TradingView Lightweight Charts

Key statistics

Previous close: NOK 8.76
Day range: NOK 8.04 – NOK 8.78
52-week range: NOK 6.90 – NOK 11.90
Volume: 12.04K
Market cap: NOK 673.64M
Avg. volume (1Y): 54.02K

Performance

1 week

-2.36%

1 month

+0.73%

3 months

-13.05%

6 months

-20.19%

Year to date

-17.23%

1 year

+14.72%

Total return, dividends included.

Company profile

Sector: Health Technology
Industry: Pharmaceuticals: Major
Country: Norway
Exchange: OSL
Shares outstanding: 76.90M
Employees: 6
ISIN: NO0010405780
Beta: -0.08

Technical view

Below averages

Where the price sits against its 50- and 200-day moving averages.

Valuation & analysis

Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.

News

Yahoo FinanceJul 07, 2026

Levicept Appoints Darlene Deptula-Hicks as CFO

Highly Experienced US-Based Public Markets Leader Strengthens Team as Company Drives Late Stage Development of LEVI-04 for OsteoarthritisSANDWICH, United Kingdom, July 07, 2026 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis (OA), today announces the appointment of Darlene Deptula-Hicks as Chief Financial Officer (CFO). Darlene has a wealth of international experience in the biotechnology and pharmaceu

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.